We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Collegium (COLL) in Focus: Stock Moves 6.9% Higher
Read MoreHide Full Article
Collegium Pharmaceutical, Inc. (COLL - Free Report) was a big mover last session, as the company saw its shares rise nearly7%on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 48.8% in the past one-month time frame.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Collegium Pharmaceutical. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Collegium currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Is COLL going up? Or down? Predict to see what others think: Up or Down.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Collegium (COLL) in Focus: Stock Moves 6.9% Higher
Collegium Pharmaceutical, Inc. (COLL - Free Report) was a big mover last session, as the company saw its shares rise nearly7%on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 48.8% in the past one-month time frame.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Collegium Pharmaceutical. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Collegium currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Collegium Pharmaceutical, Inc. Price
Collegium Pharmaceutical, Inc. Price | Collegium Pharmaceutical, Inc. Quote
Another stock worth considering in the Medical sector is Sucampo Pharmaceuticals, Inc. which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Is COLL going up? Or down? Predict to see what others think: Up or Down.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>